Siemens Healthineers Launches Capillary Testing for Core Lab Analyzers
Siemens Healthineers has launched capillary testing capabilities on Atellica analyzers after receiving CE-mark approval for 24 assays. This innovation aims to provide clinical labs with more reliable test results and improved patient access by allowing blood collection via finger prick instead of standard venipuncture. The company offers a capillary test menu that expands laboratory testing options, assisting labs in meeting diverse patient needs and addressing challenges like staffing shortages and demand for quicker turnaround times. In the U.S., select assays with capillary claims are already available, with plans for more to come after regulatory review.
Tarrytown, New York, USA, July 23, 2026 (GLOBE NEWSWIRE) —
Siemens Healthineers announced today that it has launched capillary testing on the Atellica CH, IM, and CI Analyzers after receiving CE-mark for 24 capillary blood testing claims [1], an advancement for capillary testing that offers clinical labs greater confidence in test results and higher throughput. Capillary testing on the Atellica analyzers supports the most common laboratory testing needs – including key assays that comprise the comprehensive metabolic panel, lipid panels, thyroid, Vitamin D, and HbA1c. Blood collection for capillary testing is mostly done through a finger prick or heel stick, rather than a standard blood draw (venipuncture) where a needle is inserted directly into a vein, offering greater flexibility for diverse patient testing needs.